

Issued by JPAC: 25 February 2015	Implementation: To be determined by each Service
---	---

Change Notification UK National Blood Services No. 9 - 2015

Infertility

Applies to the Tissue Donor Selection Guidelines for Live Donors, Tissue Donor Selection Guidelines for Deceased Donors, Cord Blood Donor Selection Guidelines, and Bone Marrow and PBSC Donor Selection Guidelines

Please modify the entries as follows:

i) Living and Deceased Tissue Donor Selection Guidelines

Obligatory	1. Must not donate if: a) Has ever been given human gonadotrophin of pituitary origin. b) Has received donated eggs or embryos since 1980 c) If donor knows that they have ever been treated with Metrodin HP®.
Discretionary	If treated exclusively with non-pituitary derived gonadotrophins, accept.
See if Relevant	<u>Prion Associated Diseases</u>
Additional Information	<p>The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given.</p> <p>There is a concern that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.</p> <p>Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.</p>

\Continued

Reason for Change To add additional information to clarify when the use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) ceased in the UK.

ii) Cord Blood Donor Selection Guidelines

Obligatory

1. Must not donate if:

- a) Has ever been given human gonadotrophin of pituitary origin.
- b) Has received donated eggs or embryos since 1980
- c) If donor knows that they have ever been treated with Metrodin HP®.

Discretionary

If treated exclusively with non-pituitary derived gonadotrophins, accept.

See if Relevant

Fertility Treatment
Prion Associated Diseases

Additional Information

The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given.

There is a concern that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.

Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.

Reason for Change

To add additional information to clarify when the use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) ceased in the UK.

iii) Bone Marrow and Peripheral Blood Stem Cell Guidelines

Obligatory

1. Must not donate if:

- a) Under investigation
- b) Less than 12 weeks after completion of treatment with clomiphene (Clomid)
- c) Less than 12 weeks after completion of treatment with tamoxifen.

\Continued

- d) Has ever been given human gonadotrophin of pituitary origin.
- e) Has received donated eggs or embryos since 1980
- f) If donor knows that they have ever been treated with Metrodin HP®.

Discretionary

Take care to exclude pregnancy.

If treated exclusively with non-pituitary derived gonadotrophins, accept.

See if Relevant

Prion Associated Diseases

Additional Information

The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given.

The 12 week period is an additional safeguard to avoid taking a donation early in a pregnancy.

There is a concern that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.

Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.

Reason for Change

To add additional information to clarify when the use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) ceased in the UK.

SmacLennan

Dr Sheila MacLennan

Professional Director - Joint UKBTS Professional Advisory Committee

Direct Dial: (0113) 820 8638

✉ sheila.maclennan@nhsbt.nhs.uk